ClinicalTrials.gg
RecruitingNCT06100978POSEIDON2Updated Jul 7, 2026

Patient-reported Outcome and Patient-reported Experience After Status Epilepticus

An observational study in Patient Reported Outcomes, Patient Satisfaction and Long Term Outcomes, sponsored by Versailles Hospital. Recruiting at 19 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Versailles Hospital · Observational

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
145
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 43 studies in Patient Satisfaction with a site in France — 16 open to participants now, 18 under way, none of them phase 3. Patient Satisfaction · France.

Planned enrollment
14th of 25
145 · median 150
Started
2024
with 2 others
Observational
25 of 43
5 open now
Primary completion
2027-03
later than 10 of 17 live
Registered
24th of 43
by date

Among the 43 studies in Patient Satisfaction with a site in France, this one is the 14th largest by planned enrollment of the 25 observational ones that give a count, is one of 3 that started in 2024, is one of 25 observational ones, reaches primary completion later than 10 of the 17 other live ones, and was the 24th registered.

Patient Satisfaction

882 studies on the registry are indexed under Patient Satisfaction; 205 are open to participants now.

Browse Patient Satisfaction studies →

Open to participants now

16 of the 43 studies in Patient Satisfaction with a site in France are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 102 Patient Satisfaction studies recruiting now, 63 (62%) set no upper age limit and 31 (30%) stop at 75 or younger; 14 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Patient Satisfaction with a site in France, or all of them as a file.
02

Study summary

Status epilepticus (SE) is a common life-threatening neurological emergency in which prolonged or multiple closely spaced seizures can result in long-term impairments. SE remains associated with considerable mortality and morbidity, with little progress over the last three decades. The proportion of patients who die in the hospital is about 20% overall and 40% in patients with refractory SE. Morbidity is more difficult to evaluate, as adverse effects of SE are often difficult to differentiate from those attributed to the cause of SE. Our experience suggests that nearly 50% of patients may experience long-term functional impairments. The precise description of the consequences of these functional impairments and their impact on quality of life after SE requiring intensive care management has been little studied. Indeed, if cognitive, physical and mental impairments are now identified in the populations of patients who required intensive care under the term postresuscitation syndrome (PICS), neuronal lesions consecutive to the SE itselfor to its cause could be responsible for these different functional alterations.

Thus, the following have been described: (i) cognitive disorders in the areas of attention, executive functions and verbal fluency, visual and working memory disorders, but also spatio-temporal disorders; (ii) physical disorders such as the so-called post-resuscitation polyneuromyopathy; and (iii) mental disorders such as anxiety disorders, depressive states or those related to post-traumatic stress.

Assessment and characterization of patient-reported outcomes is essential to complement the holistic assessment of clinically relevant outcomes from the patient's perspective. The POSEIDON study was a cross-sectional collection of PROs and HR-QOL components, and associated with patient functional outcomes, in those who required ICU management for status epilepticus. We propose here to continue the description of potential alterations after a subsequent ME, namely a longitudinal study (POSEIDON 2) which will also include the evaluation of patient-reported experience (PREMS) and the measurement of family burden.

03

Conditions studied

  • Patient Reported Outcomes
  • Patient Satisfaction
  • Long Term Outcomes
  • Status Epilepticus
  • Intensive Care Unit
  • Burden
  • Relatives
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All patients who meet the eligibility criteria will be offered participation in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18 years old or older
  • Patients previously included in the ICTAL registry (Status Epilepticus cohort NCT03457831)
  • Survivors after ICU management for Status Epilepticus More than 3 months and less than 5 years after ICU discharge

Exclusion criteria

Exclusion Criteria:

  • Legal guardianship
  • Opposition to participate
  • Unread and unwritten French language
  • Patient not affiliated to a Social Security system
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
145 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. percentage of global impairment of HRQoL

    percentage of global impairment of HRQoL defined by one and/or other of the physical and mental impairments (after dichotomization of the SF 36 summary scores compared to the general population) in patients managed in the ICU for or with SE. 36-Item Short Form Survey (SF-36) (HRQoL)-Ranging score\[0-100\], a high score indicate better health status.

    Time frame: at 3 month and 12 month

Secondary outcomes

  1. percentage of cognitive impairment in patients managed in the ICU for or with SE

    i)The cognitive complaints questionnaire (Questionnaire de Plainte Cognitive (QPC)(Cognition)- a score=3 or more indicate cognitive complaints

    Time frame: at 3 month and 12 month

  2. percentage of disability in patients managed in the ICU for or with SE

    The Glasgow Outcome Scale extended (Handicap)-Ranging score\[1-8\] a hight score indicate no handicap A score of 5 to 8 on the GOSE indicate a favorable outcome

    Time frame: at 3 month and 12 month

  3. percentage of physical dependency in patients managed in the ICU for or with SE

    The Lawton IADL (scale contains eight items, with a summary score from 0 (low function) to 8 (high function).and Barthel index (Dependency)-Ranging score\[0-100\], a high score indicate no dependency.

    Time frame: at 3 month and 12 month

  4. percentage of anxiety and depression in patients managed in the ICU for or with SE

    The Hospital anxiety and depression (Anxiety,Depression)-Ranging score\[0-21\] a score \> 8 indicate in each subscale a depresion or/and anxiety

    Time frame: at 3 month and 12 month

  5. percentage of post traumatic syndrome disorder in patients managed in the ICU for or with SE

    The Impact of Event Scale -Revised(post traumatic syndrome disorder)-Ranging score\[0-88\],scores higher than 24 are of concern; the higher scores indicate the severity of PTSD

    Time frame: at 3 month and 12 month

  6. score of perceived social support by the SSQ6 scale in its 2 dimensions, satisfaction and availability.

    The Social Support Questionnaire- Short Form-SSQ6 / 6 item measure of social support, with scores ranging from 0 (no social support) to 6 (very high social) and 1 (very dissatisfied) to 6 (very satisfied) for the area of satisfaction in each item or area. From these scores in the 6 domains, an average score with the support given in each of the areas.

    Time frame: at 3 month and 12 month

  7. Presence or absence Post-ICU factors associated of return to work ability in patients managed in the ICU for or with SE.

    A return to work will be interpreted by measured by the Work Productivity and Activity Impairment Questionnaire: General Health (WPAI-GH scale) The WPAI-GH consists of six questions: 1 = currently employed; 2 = hours missed due to health problems; 3 = hours missed other reasons; 4 = hours actually worked; 5 = degree health affected productivity while working (using a 0 to 10 Visual Analogue Scale (VAS)); 6 = degree health affected productivity in regular unpaid activities (VAS).. Four main outcomes can be generated from the WPAI-GH and expressed in percentages by multiplying the following scores by 100:

    Time frame: at 3 month and 12 month

  8. patient's experience of the care system.

    Score measured by the PPE 15 (Picker Patient Experience Questionnaire) of the patient's experience of the healthcare system. It consists of 15 questions distributed to seven dimensions of care: respect, coordination, information/communication/education, physical comfort, emotional support, involvement of relatives, and transitions and continuity The questions have two ("yes" or "no") to four response options ("yes"," no", "I did not need to", or "yes, to some extent"). Neutral answers, such as "I did not need to", and the most positive answer are coded as a "non-problem" (score = 0). The remaining responses are coded as "problems" (score = 1).

    Time frame: at 3 month and 12 month

  9. experience of the patient's relative at M3 and M12 of discharge from intensive care following management with or for a patient's ME.

    Score measured by ZARIT scale Zarit Burden Interview: Revised (22-items) Total score range: 0 to 88 0-21: no to mild burden 21-40: mild to moderate burden 41-60: moderate to severe burden ≥ 61: severe burden

    Time frame: at 3 month and 12 month

07

Study locations

15 of 19 sites recruiting
08

References and documents

Publications

  • Legriel S, Bernard C, Sboui G, Sigaud F, Lascarrou JB, Mayenco-Cardenal N, Chelly J, Bruel C, Mongardon N, Marzouk M, Quenot JP, Hugues R, Schnell D, Beuret P, Bailly P, Lesieur O, Argaud L, Chambon R, Jacq G. Assessment of health-related quality of life, cognitive, physical and psychological impairments in critically ill adults after status epilepticus (POSEIDON 2): protocol for a multicentre longitudinal study. BMJ Open. 2026 Mar 3;16(3):e112563. doi: 10.1136/bmjopen-2025-112563. PubMed 41775483 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Mar 2027, 34 months after the start.

Of 107 non-industry observational studies under Patient Satisfaction, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 45. This study's planned 34 months is above that.

Counting every sponsor, half of 113 studies reached it within 20 months; a quarter within 7 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2023
First posted
Oct 25, 2023
StartActual
May 25, 2024
Primary completionEst.
Mar 25, 2027
CompletionEst.
Mar 25, 2027
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06100978
Lead sponsor
Versailles Hospital
Responsible party
Jacq Gwenaelle (Investigator Coordinator, Versailles Hospital) — Principal investigator
First posted
Oct 25, 2023
Start date
May 25, 2024
Primary completion
Mar 25, 2027 (estimated)
Completion
Mar 25, 2027 (estimated)
Last update
Jul 7, 2026

Study contacts

Gwenaelle Jacq, RN,MSc,PhDc
Contact
gjacq@ght78sud.fr
33139638356
Gwenaelle Jacq, RN,MSc,PhDc
study director · CH Versailles
Stephane Legriel, MD,PhD
study director · CH Versailles

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion